Fad. Van Riet et al., Experience with high dose dexamethasone in the treatment of chronic symptomatic immune thrombocytopaenia, E AFR MED J, 76(10), 1999, pp. 571-574
Objective: To evaluate the efficacy of high dose dexamethasone (HDD) as tre
atment for symptomatic chronic immune thrombocytopaenia (ITP),
Design: A non-randomised intervention study with final evaluation one year
after treatment, comparing findings before and after intervention.
Setting: Tygerberg University Hospital, South Africa.
Participants: A consecutive sample of six children with chronic (duration m
ore than six months) ITP, The diagnosis of ITP was based on a platelet coun
t of < 100 x 10(9)/l together with appropriate clinical, laboratory and bon
e marrow findings.
Interventions: All children treated with dexamethasone 0.5 mg/kg/day intrav
enously for four days every 28 days for a total of six cycles,
Main outcome measures: A rise in platelet count maintained for a least one
year associated with the disappearance of symptoms due to thrombocytopaenia
.
Results: Treatment was easy to administer and well tolerated with transient
side effects in only two children. Three patients had a rise in platelet c
ount of > 50 x 10(9)/l during treatment and three had platelet counts of >
30 x 10(9)/l after completion of therapy but only one at one month and one
at six months after completion of the six courses respectively. None of the
patients showed a sustained rise in platelet count during and after HDD tr
eatment.
Conclusion: HDD did not cause a significant sustained rise in the platelet
count in children with chronic symptomatic ITP. If high dose prednisone and
IVIG fail, a splenectomy should be considered in children over five years
of age.